{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Fallopian+Tube&page=23",
    "query": {
      "condition": "Fallopian Tube",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 686,
    "total_pages": 69,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Fallopian+Tube&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Fallopian+Tube&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T16:42:14.892Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03531645",
      "title": "Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Neoplasms of Female Genital Organs"
      ],
      "interventions": [
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 18,
      "start_date": "2019-08-13",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-28T16:42:14.892Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03531645"
    },
    {
      "nct_id": "NCT04071392",
      "title": "Development of an Intrauterine Pressure Threshold to Confirm Tubal Occlusion",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sterilization, Female",
        "Fallopian Tube Occlusion"
      ],
      "interventions": [
        {
          "name": "Hysterosalpingogram (HSG)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2016-09-01",
      "completion_date": "2017-07-31",
      "has_results": true,
      "last_update_posted_date": "2019-12-10",
      "last_synced_at": "2026-10-28T16:42:14.892Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04071392"
    },
    {
      "nct_id": "NCT00702299",
      "title": "Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "pemetrexed disodium",
          "type": "DRUG"
        },
        {
          "name": "biologic sample preservation procedure",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2007-09",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2016-01-01",
      "last_synced_at": "2026-10-28T16:42:14.892Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00702299"
    },
    {
      "nct_id": "NCT01610206",
      "title": "A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "pazopanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Linda R Duska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 148,
      "start_date": "2012-09",
      "completion_date": "2020-12-31",
      "has_results": true,
      "last_update_posted_date": "2021-02-25",
      "last_synced_at": "2026-10-28T16:42:14.892Z",
      "location_count": 8,
      "location_summary": "Scarborough, Maine • Baltimore, Maryland • Durham, North Carolina + 5 more",
      "locations": [
        {
          "city": "Scarborough",
          "state": "Maine"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01610206"
    },
    {
      "nct_id": "NCT01853644",
      "title": "Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Epithelial Ovarian Cancer",
        "Recurrent Fallopian Tube Cancer",
        "Recurrent Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Tivozanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 110 Years · Female only"
      },
      "enrollment_count": 31,
      "start_date": "2013-06-06",
      "completion_date": "2021-05-11",
      "has_results": true,
      "last_update_posted_date": "2021-10-12",
      "last_synced_at": "2026-10-28T16:42:14.892Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Warrenville, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Warrenville",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01853644"
    },
    {
      "nct_id": "NCT06469281",
      "title": "A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer",
        "Primary Peritoneal Carcinoma",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "27T51",
          "type": "OTHER"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 90,
      "start_date": "2024-08-06",
      "completion_date": "2030-05-27",
      "has_results": false,
      "last_update_posted_date": "2026-02-03",
      "last_synced_at": "2026-10-28T16:42:14.892Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • Hackensack, New Jersey • Buffalo, New York + 2 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06469281"
    },
    {
      "nct_id": "NCT05092373",
      "title": "Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Breast Carcinoma",
        "Advanced Endometrial Carcinoma",
        "Advanced Fallopian Tube Carcinoma",
        "Advanced Hepatocellular Carcinoma",
        "Advanced Malignant Abdominal Neoplasm",
        "Advanced Malignant Female Reproductive System Neoplasm",
        "Advanced Malignant Thoracic Neoplasm",
        "Advanced Ovarian Carcinoma",
        "Advanced Primary Peritoneal Carcinoma",
        "Advanced Renal Cell Carcinoma",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "Anatomic Stage IIIB Breast Cancer AJCC v8",
        "Anatomic Stage IIIC Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Malignant Abdominal Neoplasm",
        "Malignant Solid Neoplasm",
        "Metastatic Breast Carcinoma",
        "Metastatic Endometrial Carcinoma",
        "Metastatic Fallopian Tube Carcinoma",
        "Metastatic Hepatocellular Carcinoma",
        "Metastatic Malignant Abdominal Neoplasm",
        "Metastatic Malignant Female Reproductive System Neoplasm",
        "Metastatic Malignant Thoracic Neoplasm",
        "Metastatic Ovarian Carcinoma",
        "Metastatic Primary Peritoneal Carcinoma",
        "Metastatic Renal Cell Carcinoma",
        "Prognostic Stage III Breast Cancer AJCC v8",
        "Prognostic Stage IIIA Breast Cancer AJCC v8",
        "Prognostic Stage IIIB Breast Cancer AJCC v8",
        "Prognostic Stage IIIC Breast Cancer AJCC v8",
        "Prognostic Stage IV Breast Cancer AJCC v8",
        "Stage III Fallopian Tube Cancer AJCC v8",
        "Stage III Hepatocellular Carcinoma AJCC v8",
        "Stage III Ovarian Cancer AJCC v8",
        "Stage III Primary Peritoneal Cancer AJCC v8",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage III Uterine Corpus Cancer AJCC v8",
        "Stage IIIA Fallopian Tube Cancer AJCC v8",
        "Stage IIIA Hepatocellular Carcinoma AJCC v8",
        "Stage IIIA Ovarian Cancer AJCC v8",
        "Stage IIIA Primary Peritoneal Cancer AJCC v8",
        "Stage IIIA Uterine Corpus Cancer AJCC v8",
        "Stage IIIA1 Fallopian Tube Cancer AJCC v8",
        "Stage IIIA1 Ovarian Cancer AJCC v8",
        "Stage IIIA2 Fallopian Tube Cancer AJCC v8",
        "Stage IIIA2 Ovarian Cancer AJCC v8",
        "Stage IIIB Fallopian Tube Cancer AJCC v8",
        "Stage IIIB Hepatocellular Carcinoma AJCC v8",
        "Stage IIIB Ovarian Cancer AJCC v8",
        "Stage IIIB Primary Peritoneal Cancer AJCC v8",
        "Stage IIIB Uterine Corpus Cancer AJCC v8",
        "Stage IIIC Fallopian Tube Cancer AJCC v8",
        "Stage IIIC Ovarian Cancer AJCC v8",
        "Stage IIIC Primary Peritoneal Cancer AJCC v8",
        "Stage IIIC Uterine Corpus Cancer AJCC v8",
        "Stage IIIC1 Uterine Corpus Cancer AJCC v8",
        "Stage IIIC2 Uterine Corpus Cancer AJCC v8",
        "Stage IV Fallopian Tube Cancer AJCC v8",
        "Stage IV Hepatocellular Carcinoma AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Primary Peritoneal Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Stage IV Uterine Corpus Cancer AJCC v8",
        "Stage IVA Fallopian Tube Cancer AJCC v8",
        "Stage IVA Hepatocellular Carcinoma AJCC v8",
        "Stage IVA Ovarian Cancer AJCC v8",
        "Stage IVA Primary Peritoneal Cancer AJCC v8",
        "Stage IVA Uterine Corpus Cancer AJCC v8",
        "Stage IVB Fallopian Tube Cancer AJCC v8",
        "Stage IVB Hepatocellular Carcinoma AJCC v8",
        "Stage IVB Ovarian Cancer AJCC v8",
        "Stage IVB Primary Peritoneal Cancer AJCC v8",
        "Stage IVB Uterine Corpus Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Tumor Treating Fields Therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2022-04-29",
      "completion_date": "2026-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-10-28T16:42:14.892Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05092373"
    },
    {
      "nct_id": "NCT05041257",
      "title": "Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Peritoneal Cancer",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "Mirvetuximab soravtansine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 79,
      "start_date": "2021-10-19",
      "completion_date": "2024-12-12",
      "has_results": true,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-10-28T16:42:14.892Z",
      "location_count": 11,
      "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Covington",
          "state": "Louisiana"
        },
        {
          "city": "Teaneck",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05041257"
    },
    {
      "nct_id": "NCT06824467",
      "title": "A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Sacituzumab tirumotecan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "H1 receptor antagonist",
          "type": "DRUG"
        },
        {
          "name": "H2 receptor antagonist",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen (or equivalent)",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone (or equivalent)",
          "type": "DRUG"
        },
        {
          "name": "Steroid mouthwash (dexamethasone or equivalent)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 770,
      "start_date": "2025-04-09",
      "completion_date": "2032-11-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-28T16:42:14.892Z",
      "location_count": 38,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Irvine, California + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06824467"
    },
    {
      "nct_id": "NCT02324439",
      "title": "Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Omega Nutrition cold-milled flaxseeds",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Southern Illinois University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "21 Years and older · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2015-03",
      "completion_date": "2021-03",
      "has_results": false,
      "last_update_posted_date": "2022-04-01",
      "last_synced_at": "2026-10-28T16:42:14.892Z",
      "location_count": 1,
      "location_summary": "Springfield, Illinois",
      "locations": [
        {
          "city": "Springfield",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02324439"
    }
  ]
}